Praliciguat, a clinical-stage sGC stimulator, has previously been shown to decrease blood pressure, reduce inflammation, and protect against end-organ damage in nonclinical disease models relevant to metabolic syndrome (Tobin et al., 2018; Shea et al., 2020). This evidence concerns the gene SGCB and metabolic syndrome.